Profile data is unavailable for this security.
About the company
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
- Revenue in USD (TTM)0.00
- Net income in USD-29.28m
- Incorporated2005
- Employees6.00
- LocationProMIS Neurosciences IncSuite 200, 1920 Yonge StreetTORONTO M4S 3E2CanadaCAN
- Phone+1 (416) 847-6898
- Websitehttps://www.promisneurosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc | 0.00 | -48.50m | 45.63m | 12.00 | -- | 0.623 | -- | -- | -18.65 | -18.65 | 0.00 | 6.13 | 0.00 | -- | -- | 0.00 | -112.64 | -155.80 | -123.21 | -186.20 | -- | -- | -- | -6,230.96 | -- | -280.00 | 0.00 | -- | 616.67 | -31.02 | -154.00 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 47.48m | 3.00 | -- | 4.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 47.92m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 48.28m | 75.00 | -- | 0.3754 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.35m | 48.56m | 2.00 | -- | -- | -- | -- | -0.0396 | -0.0396 | 0.00 | -0.0817 | 0.00 | -- | -- | 0.00 | -904.16 | -- | -- | -- | -- | -- | -- | -- | -- | -7.46 | -- | -- | -- | -- | -19.61 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 49.05m | 6.00 | -- | 5.34 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Lipocine Inc | 4.32m | -5.48m | 49.08m | 16.00 | -- | 3.39 | -- | 11.35 | -1.04 | -1.04 | 0.7933 | 2.61 | 0.2351 | -- | 41.82 | 270,168.10 | -29.78 | -30.54 | -32.92 | -34.86 | -- | -- | -126.66 | -194.90 | -- | -- | 0.00 | -- | 492.80 | 132.45 | 100.05 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 50.14m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -20.26m | 50.36m | 4.00 | -- | 13.08 | -- | -- | -0.9794 | -0.9794 | 0.00 | 0.1415 | 0.00 | -- | -- | 0.00 | -334.55 | -- | -870.52 | -- | -- | -- | -- | -- | -- | -2,674.49 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.06m | 50.53m | 13.00 | -- | 11.25 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.17m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -61.71m | 51.77m | 55.00 | -- | 0.624 | -- | -- | -8.44 | -8.44 | 0.00 | 11.33 | 0.00 | -- | -- | 0.00 | -47.14 | -34.75 | -54.13 | -36.82 | -- | -- | -- | -5,003.10 | -- | -- | 0.0742 | -- | -100.00 | -- | 17.80 | -- | -45.57 | -- |
| LeonaBio Inc | 0.00 | -37.72m | 53.40m | 26.00 | -- | 0.8422 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Mira Pharmaceuticals Inc | 0.00 | -28.42m | 54.02m | -- | -- | 6.75 | -- | -- | -1.52 | -1.52 | 0.00 | 0.1911 | 0.00 | -- | -- | -- | -115.28 | -- | -123.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.46 | -- | -- | -- |
| UMeWorld Inc | 7.93k | -1.32m | 54.33m | 1.00 | -- | -- | -- | 6,851.43 | -0.0148 | -0.0148 | 0.00009 | -0.0477 | 0.1253 | -- | 1.71 | 7,930.00 | -2,066.65 | -273.32 | -- | -- | -285.62 | -768.98 | -16,497.98 | -13,102.00 | -- | -2.36 | -- | -- | 136.17 | -- | -15.02 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 55.21m | 21.00 | -- | 7.80 | -- | 10.50 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
Data as of Mar 03 2026. Currency figures normalised to ProMIS Neurosciences Inc's reporting currency: US Dollar USD
11.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Trails Edge Capital Partners LPas of 03 Feb 2026 | 933.48k | 10.41% |
| Deep Track Capital LPas of 06 Feb 2026 | 66.91k | 0.75% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 13.37k | 0.15% |
| Sphera Funds Management Ltd.as of 31 Dec 2025 | 11.81k | 0.13% |
| Allostery Investments LPas of 30 Jun 2025 | 6.23k | 0.07% |
| UBS Securities LLCas of 31 Dec 2025 | 1.45k | 0.02% |
| Disciplined Equity Management, Inc.as of 31 Dec 2025 | 1.00k | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2025 | 360.00 | 0.00% |
| Desjardins Securities, Inc.as of 31 Dec 2025 | 320.00 | 0.00% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Dec 2025 | 218.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
